While the major equity indexes have experienced a choppy Q4, a number of groups within the health care sector have shown strong resilience. Pharmaceuticals and biotechs have generally outperformed the S & P 500 since the end of September, suggesting a potential safe haven play for investors concerned about market instability. Today, we profile one biotechnology company, Gilead Sciences (GILD) , and demonstrate how the long-term trend combined with short-term improvement could lead to much further upside into the year-end. Starting with the weekly chart, we can see that the major low in April was actually just a pause within a much larger uptrend phase that started back in May 2024. A weekly PPO buy signal soon after the May 2024 low ushered in a new accumulation phase that arguably continu

See Full Page